Administration of experimental treatment association (sotorasib, panitumumab 5FU) clinical trials

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

This study looks at a new combination of medicines (5-FU, Panitumumab, and Sotorasib) for older or less healthy patients with advanced bowel cancer that has a specific genetic change (KRAS G12C mutation) and can't be removed by surgery. We want to see if this combination works well and is safe as a first treatment.